{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:52:27Z","timestamp":1773971547701,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jhep.2024.03.018","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T14:45:49Z","timestamp":1710945949000},"page":"e183-e184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mycophenolate mofetil in autoimmune hepatitis: Are we ready for primetime?"],"prefix":"10.1016","volume":"81","author":[{"given":"Sagnik","family":"Biswas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Shalimar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jhep.2024.03.018_bib1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jhep.2023.11.032","article-title":"An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis","volume":"80","author":"Snijders","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.03.018_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/01.wnl.0000438226.10353.1c","article-title":"The questionable use of unequal allocation in confirmatory trials","volume":"82","author":"Hey","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jhep.2024.03.018_bib3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.03.018_bib4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference network on hepatological diseases and the international autoimmune hepatitis group","volume":"73","author":"Lohse","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.03.018_bib5","article-title":"Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease","volume":"5","author":"Zachou","year":"2023","journal-title":"JHEP Rep"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824002010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824002010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:40:06Z","timestamp":1773967206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824002010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0168827824002010"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.03.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycophenolate mofetil in autoimmune hepatitis: Are we ready for primetime?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.11.032","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}